CD19 mRNA quantification improves rituximab treatment-to-target approach: a proof of concept study.
J Neuroimmunol
; 277(1-2): 127-33, 2014 Dec 15.
Article
em En
| MEDLINE
| ID: mdl-25293807
ABSTRACT
We compared pre-amplification (PA) RT-PCR blood CD19 mRNA quantification with flow cytometry (FC), to personalize rituximab re-treatment in neuromyelitis optica spectrum disorders (NMOSDs) patients. 47 blood samples from 3 NMOSDs patients were studied. PA-RT-PCR quantified CD19 in all samples, and a positivity threshold was defined, whereas CD19+ B cells were under threshold in 31/47 samples by FC. In all samples where CD19+ B cells were above FC threshold, they resulted above the PA-RT-PCR threshold. CD19 mRNA was above threshold in 8 other samples, resulted negative by FC, and preceded the FC positivity in 7/8 samples by 1-3 months, showing major sensitivity.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
RNA Mensageiro
/
Neuromielite Óptica
/
Antirreumáticos
/
Antígenos CD19
/
Anticorpos Monoclonais Murinos
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article